The Effect of the Prognostic Nutritional Index on Chemoradiotherapy Response in Lung Cancer
Received Date : 13 Apr 2020
Accepted Date : 20 Jul 2020
Available Online : 25 Aug 2020
Doi: 10.37047/JOS.2020-75476 - Article's Language: EN
J Oncol Sci.2020;6(2):96-102
This is an open access article under the CC BY-NC-ND license
Objective: Lung cancer (LC) is the leading cause of death due to cancer worldwide. The non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprise approximately 85% of the malignant lung tumors. The prognostic nutritional index (PNI), which includes serum albumin levels and circulating lymphocyte counts, can reflect both the immunological and nutritional status of the cancer patients. In this study, we tried to evaluate the relationship between PNI and the response of chemoradiation treatment in stage III lung cancer. Material and Methods: We retrospectively reviewed the medical records of 63 patients with stage III NCSLC or SCLC disease and had undergone concurrent chemotherapy and radiotherapy. The patient characteristics, lymphocyte-neutrophil count, levels of hemoglobin, albumin, and C-reactive protein, pathologic subtype, stage of the disease, treatment modalities, chemotherapeutic agents, and chemoradiotherapy outcome after the treatment were recorded. PNI was defined as serum albumin levels(mg/dL) x 10 + total lymphocyte count (per mm3) x 0.005. PNI and neutrophil to lymphocyte ratio (NLR) were calculated before starting any treatment. Results: The patients were categorized into two groups according to the PNI (<50 or ≥50), and NLR (<.3 or ≥3). While the median overall survival was 16 months in the low PNI group, it was 27 months in the high PNI group. The cut-off value of the PNI was also its median value and was determined to be 50. Despite the numerical difference in median OS between groups, according to the PNI groups, there was no statistical difference in terms of OS. No difference was observed between NLR groups categorized for cut-off levels. None of the clinical and inflammatory markers exhibited a prognostic effect on survival in multivariate analysis. Conclusion: In this study, we observed no relationship between inflammatory markers and prognosis in patients with stage three lung cancer who underwent chemoradiation. Although the difference was statistically insignificant, the OS was numerically higher, favoring the high PNI group.
  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29. [Crossref]  [PubMed] 
  2. Chen P, Wang C, Cheng B, et al. Plasma fibrinogen and serum albumin levels (FA score) act as a promising prognostic indicator in non-small cell lung cancer. Onco Targets Ther. June 2017;10:3107-3118. [Crossref]  [PubMed]  [PMC] 
  3. Zeng Q, Xue N, Dai D, et al. A nomogram based on inflammatory factors c-reactive protein and fibrinogen to predict the prognostic value in patients with resected non-small cell lung cancer. J Cancer. 2017;8(5):744-753 [Crossref]  [PubMed]  [PMC] 
  4. Stinchcombe TE, Zhang Y, Vokes EE, et al. Pooled analysis of individual patient data on concurrent chemoradiotherapy for stage III non-small-cell lung cancer in elderly patients compared with younger patients who participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol. 2017;35(25):2885-2892. [Crossref]  [PubMed]  [PMC] 
  5. Antoni D, Mornex F. Chemoradiotherapy of locally advanced nonsmall cell lung cancer: state of the art and perspectives. Curr Opin Oncol. 2016;28(2):104-109. [Crossref]  [PubMed] 
  6. Pless M, Stupp R, Ris HB, et al; SAKK Lung Cancer Project Group. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet. 2015;386(9998):1049-1056. [Crossref]  [PubMed] 
  7. Feng W, Fu XL, Cai XW, et al. Patterns of local-regional failure in completely resected stage IIIA(N2) non-small cell lung cancer cases: implications for postoperative radiation therapy clinical target volume design. Int J Radiat Oncol Biol Phys. 2014;88(5):1100-1107. [Crossref]  [PubMed] 
  8. Suzuki K, Nagai K, Yoshida J, et al. Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma: a comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses. Cancer. 1999;86(10):1976-1984. [Crossref]  [PubMed] 
  9. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European lung cancer working party. J Clin Oncol. 1995;13(5):1221-1230. [Crossref]  [PubMed] 
  10. Teramukai S, Kitano T, Kishida Y, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer. 2009;45(11):1950-1958. [Crossref]  [PubMed] 
  11. Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (MGPS) predicts cancer survival independent of tumour site: a glasgow inflammation outcome study. Br J Cancer. 2011;104(4):726-734. [Crossref]  [PubMed]  [PMC] 
  12. Fogar P, Sperti C, Basso D, et al. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas. 2006;32(1):22-28. [Crossref]  [PubMed] 
  13. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A glasgow inflammation outcome study. Eur J Cancer. 2011;47(17):2633-2641. [Crossref]  [PubMed] 
  14. Cannon NA, Meyer J, Iyengar P, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J Thorac Oncol. 2015;10(2):280-285. [Crossref]  [PubMed] 
  15. Shimizu K, Okita R, Saisho S, et al. Prognostic nutritional index before adjuvant chemotherapy predicts chemotherapy compliance and survival among patients with non-small-cell lung cancer. Ther Clin Risk Manag. 2015;11:1555-1561. [Crossref]  [PubMed]  [PMC] 
  16. Kinoshita A, Onoda H, Imai N, et al. Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br J Cancer. 2012;107(6):988-993. [Crossref]  [PubMed]  [PMC] 
  17. Sheng J, Yang YP, Ma YX, et al. Low prognostic nutritional index correlates with worse survival in patients with advanced NSCLC following EGFR-TKIS. PLoS One. 2016;11(1):e0147226. [Crossref]  [PubMed]  [PMC] 
  18. Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. December 2010;9:69. [Crossref]  [PubMed]  [PMC] 
  19. Onodera T, Goseki N, Kosaki G. [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients]. Nihon Geka Gakkai Zasshi. 1984;85(9):1001-1005. [PubMed] 
  20. Hirahara N, Tajima Y, Fujii Y, et al. Preoperative prognostic nutritional index predicts long-term surgical outcomes in patients with esophageal squamous cell carcinoma. World J Surg. 2018;42(7):2199-2208. [Crossref]  [PubMed]  [PMC] 
  21. Hong S, Zhou T, Fang W, et al. The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients. Tumour Biol. 2015;36(5):3389-3397. [Crossref]  [PubMed] 
  22. Nakatani M, Migita K, Matsumoto S, et al. Prognostic significance of the prognostic nutritional index in patients with recurrent esophageal squamous cell carcinoma. Nutr Cancer. 2018;70(3):467-473. [Crossref]  [PubMed] 
  23. Sun K, Chen S, Xu J, Li G, He Y. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140(9):1537-1549. [Crossref]  [PubMed] 
  24. Yang Y, Gao P, Song Y, et al. The prognostic nutritional index is a predictive indicator of prognosis and postoperative complications in gastric cancer: a meta-analysis. Eur J Surg Oncol. 2016;42(8):1176-1182 [Crossref]  [PubMed] 
  25. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411(6835):380-384. [Crossref]  [PubMed] 
  26. d'Engremont C, Vernerey D, Pointet AL, et al. Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study. BMC Cancer. 2016;16(1):823. [Crossref]  [PubMed]  [PMC] 
  27. Kobayashi N, Usui S, Kikuchi S, et al. Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer. Lung Cancer. 2012;75(2):223-227. [Crossref]  [PubMed] 
  28. Saito H, Kono Y, Murakami Y, et al. Prognostic significance of pre- and postoperative lymphocyte counts in patients with gastric cancer. Dig Surg. 2019;36(2):137-143. [Crossref]  [PubMed] 
  29. Chen XL, Xue L, Wang W, et al. Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study. Oncotarget. 2015;6(38):41370-41382. [Crossref]  [PubMed]  [PMC] 
  30. Schwegler I, von Holzen A, Gutzwiller JP, Schlumpf R, Mühlebach S, Stanga Z. Nutritional risk is a clinical predictor of postoperative mortality and morbidity in surgery for colorectal cancer. Br J Surg. 2010;97(1):92-97. [Crossref]  [PubMed] 
  31. Watanabe M, Kinoshita T, Tokunaga M, Kaito A, Sugita S. Complications and their correlation with prognosis in patients undergoing total gastrectomy with splenectomy for treatment of proximal advanced gastric cancer. Eur J Surg Oncol. 2018;44(8):1181-1185. [Crossref]  [PubMed] 
  32. Peng Y, Li Z, Zhang S, et al. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients. Int J Cancer. 2014;135(11):2687-2696. [Crossref]  [PubMed] 
  33. Feng JF, Chen QX. Significance of the prognostic nutritional index in patients with esophageal squamous cell carcinoma. Ther Clin Risk Manag. 2014;10:1-7. [Crossref]  [PubMed]  [PMC] 
  34. Pinato DJ, North BV, Sharma R. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br J Cancer. 2012;106(8):1439-1445. [Crossref]  [PubMed]  [PMC] 
  35. Nozoe T, Ninomiya M, Maeda T, Matsukuma A, Nakashima H, Ezaki T. Prognostic nutritional index: a tool to predict the biological aggressiveness of gastric carcinoma. Surg Today. 2010;40(5):440-443. [Crossref]  [PubMed] 
  36. Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S, Nakao A. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 2011;98(2):268-274. [Crossref]  [PubMed] 
  37. Hu Y, Shen J, Liu RK, et al. Prognostic value of pretreatment prognostic nutritional index in non-small cell lung cancer: a systematic review and meta-analysis. Int J Biol Markers. 2018;33(4):372-378. [Crossref]  [PubMed] 
  38. Mori S, Usami N, Fukumoto K, et al. The significance of the prognostic nutritional index in patients with completely resected non-small cell lung cancer. PLoS One. 2015;10(9):e0136897. [Crossref]  [PubMed]  [PMC] 
  39. Kos FT, Hocazade C, Kos M, et al. Assessment of prognostic value of "neutrophil to lymphocyte ratio" and "prognostic nutritional index" as a sytemic inflammatory marker in non-small cell lung cancer. Asian Pac J Cancer Prev. 2015;16(9):3997-4002. [Crossref]  [PubMed] 
  40. Deng C, Zhang N, Wang Y, et al. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIS. Medicine (Baltimore). 2019;98(33):e16875. [Crossref]  [PubMed]  [PMC] 
  41. Liu J, Li S, Zhang S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal. 2019;33(8):e22964. [Crossref]  [PubMed] 
  42. Wang Z, Wang Y, Zhang X, Zhang T. Pretreatment prognostic nutritional index as a prognostic factor in lung cancer: review and meta-analysis. Clin Chim Acta. November 2018;486:303-310. [Crossref]  [PubMed] 
  43. Tong YS, Tan J, Zhou XL, Song YQ, Song YJ. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med. 2017;15(1):221. [Crossref]  [PubMed]  [PMC] 
  44. McSorley MA, Alberg AJ, Allen DS, et al. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol. 2007;109(4):933-941. [Crossref]  [PubMed] 
  45. Kemik O, Kemik AS, Begenik H, et al. The relationship among acute-phase responce proteins, cytokines, and hormones in various gastrointestinal cancer types patients with cachectic. Hum Exp Toxicol. 2012;31(2):117-125. [Crossref]  [PubMed] 
  46. Fu J, Yang X. The prognostic value of the c-reactive protein/prognostic nutritional index ratio in stage III and IV laryngeal cancer patients treated with radiotherapy. Cureus. 2019;11(5):e4648. [Crossref]  [PubMed]  [PMC]